There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynex (ZYXI – Research Report) and Arcutis Biotherapeutics (ARQT – Research Report) with bullish sentiments.
Zynex (ZYXI)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Zynex, with a price target of $20.00. The company’s shares closed last Thursday at $9.75.
According to TipRanks.com, Chen ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Zynex is a Moderate Buy with an average price target of $20.00.
See the top stocks recommended by analysts >>
Arcutis Biotherapeutics (ARQT)
In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $57.00. The company’s shares closed last Thursday at $10.00, close to its 52-week low of $7.25.
According to TipRanks.com, Ear is a 4-star analyst with an average return of
Arcutis Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $43.25, which is a 312.7% upside from current levels. In a report issued on July 17, Guggenheim also maintained a Buy rating on the stock with a $38.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZYXI:
